Last updated on February 2019

Plasma-Lyte 148 versUs Saline Study


Brief description of study

The aim of PLUS is to conduct a multi-centre, blinded, randomised, controlled trial (RCT) to determine whether fluid resuscitation and therapy with a "balanced" crystalloid solution (Plasma-Lyte 148) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline)

Detailed Study Description

Fluid resuscitation is a fundamental component of the management of acutely and critically ill patients and the choice of fluid is a longstanding issue of debate.

Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by emerging evidence that suggests its high chloride content may have clinically important adverse effects and that resuscitation with so-called "balanced" or "buffered" crystalloids (such as Plasma-Lyte 148) offer patients better outcomes.

Given the limitations of current evidence, there is now a scientific, ethical and health economic imperative to provide an accurate and reliable estimate of the comparative risks versus benefit of Plasma-Lyte 148 versus 0.9% saline.

The PLUS study is a prospective, multi-centre, parallel group, concealed, blinded, randomised, controlled trial.

The study will test the hypothesis that in a heterogeneous population of critically ill adults, random assignment to Plasma-Lyte 148 for intravascular volume resuscitation and crystalloid fluid therapy in the Intensive Care Unit (ICU) results in different 90-day all-cause mortality when compared with random assignment to 0.9% sodium chloride (saline) for the same treatment.

Each patient who meets all inclusion criteria and no exclusion criteria will be randomised to receive either Plasma-Lyte 148 or 0.9% saline for all resuscitation episodes and for all compatible crystalloid therapy while in ICU for up to 90 days after randomisation. Other crystalloid fluids may be used as carrier fluids for the infusion of any drug for which either Plasma-Lyte 148 or 0.9% saline is considered incompatible.The study treatments will be supplied in identical 1000 ml bags and treatment assignment will be concealed.

The volume of study fluid being administered will be titrated against clinical endpoints determined by the treating clinicians and reviewed as clinically appropriate during the period of resuscitation and ICU treatment.

Clinical Study Identifier: NCT02721654

Find a site near you

Start Over

Robina Hospital

Robina, Australia
  Connect »

Bendigo Hospital

Bendigo, Australia
  Connect »

Gosford Hospital

Gosford, Australia
  Connect »

Wollongong Hospital

Wollongong, Australia
  Connect »

North Shore Hospital

Takapuna, New Zealand
  Connect »

Middlemore Hospital

Auckland, New Zealand
  Connect »

Wellington Hospital

Newtown, New Zealand
  Connect »

Waikato Hospital

Hamilton, New Zealand
  Connect »

Hawkes Bay

Hastings, New Zealand
  Connect »

Christchurch Hospital

Christchurch, New Zealand
  Connect »

Dandenong Hospital

Dandenong, Australia
  Connect »

Hutt Hospital

Lower Hutt, New Zealand
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Nelson Hospital

Nelson, New Zealand
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »

Rotorua Hospital

Rotorua, New Zealand
  Connect »

Redcliffe Hospital

Redcliffe, Australia
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

Nepean

Penrith, Australia
  Connect »

Frankston Hospital

Frankston, Australia
  Connect »

Tauranga Hospital

Tauranga, New Zealand
  Connect »

Toowoomba Hospital

Toowoomba, Australia
  Connect »